The profile of microRNA expression and potential role in the regulation of drug-resistant genes in cisplatin and paclitaxel resistant ovarian cancer cell lines

Ovarian cancer is the most lethal gynecological malignancy. The high mortality results from late diag-nosis and the development of drug resistance. Drug resistance results from changes in the expression of different drug-resistance genes that may be regulated miRNA. The main aim of our study was to detect changes in miRNA expression levels in two cisplatin (CIS) and two paclitaxel (PAC) - resistant vari-ants of the A2780 drug-sensitive ovarian cancer cell line — by miRNA microarray The human ovarian carcinoma A2780 cell line was purchased from ATCC. A2780 sublines that were resistant to CIS [A2780CR1, A2780CR2 (A2780 cisplatin resistant)], and PAC [A2780PR1 and A2780PR2 (A2780 paclitaxel resistant)] were obtained by exposing A2780 cells to the relevant drugs at gradually increasing concentrations. The final con-centrations used to select the resistant cells were 1000 ng/ml of CIS for both A2780CR1 and A2780CR2 cell lines, 300 ng/ml of PAC for A2780PR1 cell line and 1100 ng/ml of PAC for A2780PR2 cell line